Uncategorized
Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Share on Google+
Google+
Email this to someone
email

ImmunoPrecise Signs Large Pharma Antibody Development Agreement

 

 

 

 

 

IMMUNOPRECISE ANTIBODIES LTD. (TSX-V: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed an agreement and initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company, to discover novel antibodies using ImmunoPrecise’s proprietary hybridoma technology.

 

 

ImmunoPrecise’s hybridoma platform allows for the selection of rare and slow-growing, IgG positive, monoclonal hybridomas in a semi-solid media format. Coupled with proprietary and abbreviated immunization regimes, the ability to sort cells and characterize and optimize lead candidates, ImmunoPrecise’s platform allows for streamlined processes, condensed timelines, and the early identification of developability issues, mitigating the risk of significant losses in time and money.

 

 

Under this multi-year development agreement, this global pharmaceutical company receives contract research services using ImmunoPrecise’s methods of discovering and developing antibodies in OmniAbĀ® transgenic animals (Ligand Pharmaceuticals, NASDAQ:LGND), and intellectual property rights to develop and commercialize any resulting therapeutics.

 

 

The Agreement stipulates certain confidential provisions, including, at this stage, the pharmaceutical company’s identity, target and the monetary size of contract.

 

 

ImmunoPrecise is currently in negotiations with several top 10 global pharmaceutical companies investigating the use of ImmunoPrecise’s three full-service platforms, its advanced hybridoma platform, its proprietary and high demand B-cell selectplatform, and its phage display library platform. All three can be optimally leveraged for antibody discovery using various transgenic and wild-type animal strains.

 

 

“ImmunoPrecise can uniquely leverage three powerful platforms for antibody discovery to offer comprehensive campaigns that have the potential to deliver the antibody sequence diversity required to rapidly select the best lead candidates for further advancement” said Jennifer Bath, CEO and President of ImmunoPrecise Antibodies. “We’ve seen very strong interest in our diverse line of development platforms from a number of leading global pharmaceutical and biotech companies. ”

 

 

About ImmunoPrecise. 

 

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

 

 

ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express and ModiQuest Research, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

 

 

The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hyridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

 

Posted October 10, 2018

Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Share on Google+
Google+
Email this to someone
email

MORE or "UNCATEGORIZED"


Netcoins Lists Bitcoin SV (BSV)

Netcoins Holdings Inc. (CSE: NETC) (OTC: GARLF) (WKN: 1WJ) is ple... READ MORE

December 7, 2018

Organigram obtains $10M loan from Farm Credit Canada to continue to expand Moncton campus

Organigram Holdings Inc. (TSX-V: OGI) (OTCQX: OGRMF), the parent ... READ MORE

December 7, 2018

Fimbrion and GSK Identify Novel, Antibiotic-Sparing Development Candidate for Urinary Tract Infections

Fimbrion Therapeutics, Inc. announced that under its joint resear... READ MORE

December 6, 2018

Four wind farms commissioned in France

Boralex Inc. (TSX:BLX) is pleased to announce commercial co... READ MORE

December 6, 2018

ATS Announces Acquisition of Intellectual Property Assets of Transformix

ATS Automation Tooling Systems Inc. (TSX: ATA) an industry-leadin... READ MORE

December 6, 2018

Copyright 2018 The Venture Report